Gene based therapy for sickle cell disease in low and middle income countries insights from the Gambia

Abstract Sickle Cell Disease (SCD) remains a significant global health burden, disproportionately affecting low- and middle-income countries (LMICs), particularly in sub-Saharan Africa. Recent advancements in gene-based therapies, including CRISPR-Cas9 technologies like Casgevy and lentiviral treatm...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Rangarirai Makuku, Fiona McGowan Martha Hutton, Leander Penaso Marquez, Sunny O. Abarikwu, Marcarious M. Tantuoyir, Muhammed Camara, Momodou S. Jallow, Ernest Moyo, Lindelwa Phakamile Mmema, Michael P. K. Mendy, Kelvin Thomas, Emmanuel Lawal
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Springer 2026-05-01
Saila:	Discover Public Health
Gaiak:	Sickle cell disease Gene therapy CRISPR-Cas9 Global health equity Low- and Middle-Income Countries (LMICs) Casgevy
Sarrera elektronikoa:	https://doi.org/10.1186/s12982-026-01970-7
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!